益佰制药（600594.SH）2月24日在投资者互动平台表示，您好，我司建立财务管理中心，并未建立财 务共享中心。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：尊敬的董秘，您好！ 1、请问贵公司是否已经建立财务 共享中心？哪年建立的？ 2、财务共享中心在技术上采用了哪些自动化或智能化工具？数字化程度按照 0-10打分得几分？ 3、财务共享中心的数量有几个？这些中心的设立是基于地理区域划分，还是按业务 板块划分？ ...

证券日报网讯 2月24日，益佰制药在互动平台回答投资者提问时表示，公司建立财务管理中心，并未建 立财务共享中心。 （文章来源：证券日报） ...

Core Viewpoint - Yibai Pharmaceutical (600594.SH) is facing significant operational challenges, with projected net losses for 2025 and a substantial decline in total assets over the past seven years [1][12]. Financial Performance - The company expects a net profit attributable to shareholders of between -285 million to -342 million yuan for 2025, indicating a loss [2]. - Revenue is anticipated to decrease by 14% in 2025 due to reduced sales of key products, despite a projected 18% decrease in costs [2]. - Historical performance shows that from 2022 to 2024, Yibai Pharmaceutical reported revenues of 2.735 billion, 2.821 billion, and 2.174 billion yuan, with significant year-on-year declines [3]. Product Issues - The core product, Aidi Injection, has faced production halts due to regulatory investigations, impacting revenue significantly [4]. - The company has also received a suspension notice for another product, Pediatric Cough Syrup, due to compliance issues [6][7]. Asset Decline - Total assets have decreased from 7.465 billion yuan in Q3 2018 to 3.838 billion yuan in Q3 2025, a reduction of over 3.6 billion yuan, or approximately 49% [1][12]. Cost Structure - Sales expenses for the company reached 621 million yuan in the first three quarters of 2025, accounting for about 43% of total revenue, while R&D expenses were only 62.4 million yuan, approximately 4.3% of revenue [9][10]. - Cumulatively, sales expenses from 2018 to 2024 exceeded 10.527 billion yuan, indicating a heavy reliance on sales over research and development [11].

长江商报消息 ●长江商报记者 黄聪 当下，益佰制药（600594.SH）的经营指标大多正在大滑坡。 1月21日晚间，益佰制药公告显示，公司预计2025年度实现归属于母公司所有者的净利润（简称"归母净 利润"）为-2.85亿元至-3.42亿元；实现归属于母公司所有者的扣除非经常性损益后的净利润（简称"扣 非净利润"）为-2.8亿元至-3.36亿元。 益佰制药介绍，2025年，公司主要产品销售减少，导致公司收入预计下降14%。 2024年4月，益佰制药公告显示，监管部门对公司开展检查时，发现公司涉嫌在艾迪注射液前提取过程 中部分工序未严格按照工艺规程进行操作，不符合《药品生产质量管理规范》的规定，公司被依法立案 调查。 艾迪注射液为益佰制药的核心产品，目前，公司尚未发布其复产消息。 长江商报记者发现，2018年三季度末，益佰制药资产总额达74.65亿元，而截至2025年三季度末，公司 资产总额仅有38.38亿元，7年间减少超过36亿元，降幅约49%，几近腰斩。 归母净利最高预亏3.42亿 长江商报记者发现，近四年来，益佰制药有三年出现巨额亏损。 2022年至2024年，益佰制药营业收入分别为27.35亿元、28. ...

Core Viewpoint - Yibai Pharmaceutical is facing significant survival challenges, with a projected net profit loss of 285 million to 342 million yuan for 2025, marking the second consecutive year of substantial losses due to production violations and compliance issues [1][2] Group 1: Financial Performance - The company expects a net profit loss attributable to shareholders of 285 million to 342 million yuan for 2025, with a similar loss of 317 million yuan in 2024, indicating no improvement [2] - Revenue is projected to decline by 14% in the reporting period, while costs are expected to decrease by 18%, yet costs will still exceed revenue, leading to losses [6] - Sales expenses from 2022 to 2024 were excessively high, reaching 1.196 billion, 1.238 billion, and 1.097 billion yuan, accounting for 43% to 50% of revenue, while R&D expenses were only 127 million, 112 million, and 101 million yuan [5] Group 2: Product Issues - The core product, Aidi Injection, has been suspended due to production violations, including improper processing and inaccurate record-keeping, leading to significant revenue loss [2][3] - Aidi Injection generated revenues of 737 million, 693 million, 480 million, and 473 million yuan from 2020 to 2023, constituting 21.61%, 20.71%, 17.57%, and 16.77% of total revenue, respectively [3] - The company also faced issues with its pediatric cough syrup, which was halted due to non-compliance in production record-keeping, further exposing its compliance weaknesses [3] Group 3: Compliance and Management - Yibai Pharmaceutical has stated that it adheres to GMP standards and has established a drug safety committee to oversee production processes and compliance [4] - The company has been under scrutiny from regulatory bodies due to its high sales expenses, with the Shanghai Stock Exchange issuing inquiries regarding the legitimacy and compliance of these expenses [5] Group 4: Strategic Response - To address its challenges, Yibai Pharmaceutical plans to implement a "one ship, two wings" development strategy, focusing on its pharmaceutical core business while expanding into healthcare services and wellness sectors [7] - The company aims to optimize marketing resource allocation, explore potential in dormant products, and enhance operational efficiency through supply chain optimization and digital improvements [7]

Group 1 - Riel Group's shares have been suspended from trading since December 1, 2025, due to concerns raised by auditors regarding related payments, leading to the establishment of an independent investigation committee [1] - The company has delayed the publication of its 2025 interim results and report, highlighting the importance of compliance and governance in listed companies [1] - The investigation's outcome remains uncertain, raising market concerns and emphasizing the need for strict adherence to governance standards in the industry [1] Group 2 - Aotai Biotech plans to repurchase its shares using 100 million to 200 million RMB of funds raised from its initial public offering, with a buyback price not exceeding 85 RMB per share [2] - This move reflects the company's confidence in its value and aims to enhance shareholder returns by reducing registered capital through share cancellation [2] - The buyback initiative is seen as a positive response to market conditions and aims to boost investor confidence [2] Group 3 - Yibai Pharmaceutical expects a net loss attributable to shareholders of 285 million to 342 million RMB for 2025, with a projected revenue decline of 14% due to decreased sales of its main products [3] - Despite a forecasted 18% reduction in costs, expenses are still expected to exceed revenue, leading to continued losses [3] - The company plans to recognize goodwill impairment of 110 million to 132 million RMB, further exacerbating its financial challenges [3] Group 4 - Heng Rui Medicine has received approval for clinical trials of two drugs, SHR-7787 and Abedilizumab, from the National Medical Products Administration [4] - The approval underscores the company's strength in innovative drug development and enhances its product pipeline in the oncology sector [4] - The advancement of these clinical trials is expected to solidify Heng Rui's position in the industry and contribute to the growth of cancer treatment options [4]

Core Viewpoint - Guizhou Yibai Pharmaceutical Co., Ltd. is forecasting a significant net loss for the year 2025, with expected losses ranging from 342 million to 285 million yuan [2][3]. Financial Performance Summary - The company anticipates a net profit attributable to shareholders of the parent company for 2025 to be between -342 million yuan and -285 million yuan, indicating a loss [2][3]. - The expected net profit after deducting non-recurring gains and losses is projected to be between -336 million yuan and -280 million yuan [2][3]. - For the previous year, 2024, the total profit was -332.52 million yuan, with a net profit attributable to shareholders of -317.22 million yuan [5]. Earnings Per Share - The earnings per share for the previous year (2024) was reported at -0.402 yuan [6]. Reasons for Expected Loss - The primary reasons for the anticipated loss include a 14% decrease in sales of major products, leading to a decline in revenue, despite an 18% expected reduction in costs [7]. - The company plans to recognize goodwill impairment provisions between 110 million and 132 million yuan, which will further increase the losses [7].

（文章来源：证券日报） 证券日报网讯 1月21日，益佰制药发布公告称，公司预计2025年度实现归属于母公司所有者的净利润 为-34，200万元到-28，500万元，将出现亏损；预计归属于母公司所有者的扣除非经常性损益后的净利 润为-33，600万元到-28，000万元。 ...

Group 1 - The core viewpoint of the article is that Yibai Pharmaceutical (600594) is expected to report a net profit loss of between 285 million yuan and 342 million yuan for the year 2025 [1] - The company anticipates a 14% decline in revenue due to reduced sales of its main products [1] - Although the company's cost expenses are expected to decrease by 18%, the total cost expenses will still exceed revenue, leading to the projected loss [1] Group 2 - The financial department of the company plans to recognize an impairment provision for goodwill between 110 million yuan and 132 million yuan based on preliminary impairment testing results [1] - This impairment provision is expected to further increase the company's losses for the period [1]

Core Viewpoint - Yibai Pharmaceutical (600594.SH) is expected to report a net loss attributable to shareholders of the parent company ranging from -342 million to -285 million yuan for the fiscal year 2025, indicating a significant downturn in financial performance [1] Group 1: Financial Performance - The company's main product sales have decreased, leading to an anticipated revenue decline of 14% [1] - Although the company's cost expenses are expected to decrease by 18%, the total cost expenses will still exceed revenue, resulting in a loss for the period [1] Group 2: Impairment and Accounting - Based on preliminary impairment testing results, the financial department anticipates recognizing goodwill impairment provisions between 110 million and 132 million yuan, which will further increase the company's losses [1]